In 2000, OHSU Advanced Imaging Research Center (AIRC) scientists developed the Shutter-Speed Model (“SSM”) for analysis of Dynamic-Contrast-Enhanced (“DCE-MRI”) data. Later, they realized SSM is not just another pharmacokinetic “model,” but actually a new paradigm (“SSP”). The SSP enables more accurate MRI measure of, among other parameters, Ktrans, the rate constant for contrast agent molecule movement between capillaries and extravascular tissue.
The researchers determined that systematic errors in the standard tracer pharmacokinetic paradigm “SP” Ktrans value, as compared to the SSM Ktrans value, resulted in a large difference, ΔKtrans, in malignant breast tissue, but not in healthy tissue. In other words, the SP underestimates Ktrans precisely in malignant tumors. As reported in the scientists’ 2011 Radiology article, pathologic analyses revealed 20 malignant and 72 benign lesions in 89 high-risk women (age range, 28–83 years), wherein the 92 suspicious lesions received positive findings at current standard of care MRI. Remarkably, the MRI Breast Cancer Detection Technology achieved 98.6% specificity at 100% sensitivity. This could avoid many unnecessary breast biopsies. Similar prostate cancer results are forthcoming.
Potentially even more important, the lab’s 2014 NMR in Biomedicine paper shows that SSP is capable of mapping intra-tumor metabolic activity, and its focal response to breast cancer therapy. No other technique can do this.
Co-inventor Charles Springer and licensing associate Arvin Paranjpe will co-present this licensing case study at TTBD’s next Lunch & Learn event on Thursday, Feb. 26, from 12 to 1 p.m. in Mackenzie Hall on the Marquam Hill Campus. For a sneak peek into the AIRC group, glance over their hilarious ice bucket challenge video.